Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
Go back to Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)| (NASDAQ: ABUS) | Delayed: 4.52 -0.03 (0.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.55 | 52 Week High | $5.88 | |||
| Open | $4.60 | 52 Week Low | $2.65 | |||
| Day High | $4.79 | P/E | N/A | |||
| Day Low | $4.47 | EPS | $0.00 | |||
| Volume | 5,297,692 | |||||
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 286.41 +8.32 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $278.09 | 52 Week High | $109.10 | |||
| Open | $278.42 | 52 Week Low | $31.38 | |||
| Day High | $286.67 | P/E | N/A | |||
| Day Low | $278.17 | EPS | $-1.45 | |||
| Volume | 1,420,426 | |||||
